<SEC-DOCUMENT>0000950123-11-047883.txt : 20110510
<SEC-HEADER>0000950123-11-047883.hdr.sgml : 20110510
<ACCEPTANCE-DATETIME>20110510090025
ACCESSION NUMBER:		0000950123-11-047883
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110510
FILED AS OF DATE:		20110510
DATE AS OF CHANGE:		20110510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		11825865

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>w82755e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>Form&nbsp;6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16<BR>
OR 15d-16 UNDER THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For the month of May, 2011</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Commission File Number <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Novogen Limited</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Translation of registrant&#146;s name into English)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
140 Wicks Road, North Ryde, NSW, Australia<BR>

(Address of principal executive office)<BR>

<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Form&nbsp;20-F <FONT style="font-family: Wingdings">&#254;</FONT> Form 40-F <FONT style="font-family: Wingdings">&#111;</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(l): <FONT style="font-family: Wingdings">&#111;</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Note: Regulation&nbsp;S-T Rule&nbsp;101 (b)( I) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security holders.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule lO1(b)(7): <FONT style="font-family: Wingdings">&#111;</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Note: Regulation&nbsp;S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country
exchange on which the registrant&#146;s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant&#146;s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule l2g3-2(b) under the
Securities Exchange Act of 1934. Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with
Rule&nbsp;12g3-2(b):</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">









<!-- link1 " SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf </B>by the undersigned, thereunto duly authorized.</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Novogen Limited</B><BR>
(Registrant)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left"><B>/s/  Mark Hinze</B>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Mark Hinze&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Date 10 May, 2011</B></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ASX &#038; MEDIA RELEASE<BR>
10 MAY, 2011</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><IMG src="w82755w8275500.gif" alt="(Novogen logo)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>NOVOGEN ANNOUNCES CLOSING OF ASSET PURCHASE AGREEMENT WITH MARSHALL EDWARDS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Sydney Australia &#151; 10 May, 2011 &#151; Novogen Limited (ASX: NRT; NASDAQ: NVGN) today announced the
closing of the asset purchase agreement entered into on 21 December, 2010, between the Company and
its subsidiary Marshall Edwards, Inc., an oncology company focused on the clinical development of
novel anti-cancer therapeutics targeting cancer metabolism.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In this transaction, Novogen sold its Isoflavone-based intellectual property portfolio to its
majority owned subsidiary, Marshall Edwards, Inc. in a stock based transaction. The closing of the
transaction follows approval at a meeting of Novogen shareholders on 6 May, 2011. The Marshall
Edwards shareholders had previously approved the purchase at its AGM on 13 April, 2011.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In exchange for the assets sold, Novogen has received 1,000 shares of Class&nbsp;A Preferred Stock which
is convertible into 4,827 shares of Marshall Edwards common stock for an aggregate of 4,827,000
shares. The shares are valued in total at $4&nbsp;million based on the volume weighted average price
over the 20 trading days prior to the date of the execution of the asset purchase agreement. Should
any of the acquired assets achieve a statistically significant result in a Phase II clinical trial
or the first patient is enrolled in a Phase III clinical trial, each share of Class&nbsp;A Preferred
Stock not already converted will become convertible into 9,654 shares of Marshall Edwards common
stock.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In making the announcement, Mr.&nbsp;William Rueckert, Chairman stated: &#147;The consolidation of this
exciting portfolio of assets with the experienced management team at Marshall Edwards will give the
Novogen shareholders an excellent opportunity to benefit from the future development of these drug
candidates.&#148;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;Dan Gold, Marshall Edwards President and Chief Executive Officer said the following: &#147;The
closing of this strategic transaction gives us, once and for all, the flexibility to develop and
partner these valuable assets and enables us to explore other potential drug candidates and
indications within the portfolio. We look forward to entering the clinic with two next-generation
drug candidates, NV-143 and NV-344, this year.&#148;</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Novogen Limited</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney,
Australia. Novogen has a consumer healthcare business, conducts research and development on
oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan
technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of
companies can be found at <U>www.novogen.com</U>.</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Marshall Edwards</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical
development of novel anti-cancer therapeutics. The Company&#146;s lead programs focus on two families
of small molecules that result in the inhibition of tumour cell metabolism. The first and most
advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second
is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344.
Both programs are expected to advance into the clinic in 2011. For more information, please visit
<U>www.marshalledwardsinc.com</U>.</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"># # #
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the intended use. Statements included in this
press release that are not historical in nature are &#147;forward-looking statements&#148; within the meaning
of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. You should
be aware that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management&#146;s current expectations and are subject to
a number of risks and uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties or differences in
interpretation in clinical trial results; our inability to maintain or enter into, and the risks
resulting from our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution of any products;
competitive factors; our inability to protect our patents or proprietary rights and obtain
necessary rights to third party patents and intellectual property to operate our business; our
inability to operate our business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes; government regulation; changes
in industry practice; and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking statements.</I></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; FONT-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="66%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ISSUED FOR</B><BR><BR>
<B>LISTINGS</B><BR><BR>
<B>FOR FURTHER<BR>
INFORMATION</B><BR>&nbsp;<BR><BR>
<B>FOR
FURTHER<BR>
INFORMATION</B><BR>&nbsp;<BR>&nbsp;<BR><BR>
<B>ISSUED
BY<BR>
CONTACT</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>:</B><BR><BR>
<B>:</B><BR><BR>
<B>:</B><BR>
&nbsp;<BR>
&nbsp;<BR><BR>
<B>:</B><BR>
&nbsp;<BR>
&nbsp;<BR>
&nbsp;<BR><BR>
<B>:<BR>
:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>NOVOGEN LIMITED</B><BR><BR>
<B>ASX (CODE NRT), NASDAQ (CODE NVGN).</B><BR><BR>
<B>MR BILL RUECKERT, CHAIRMAN, NOVOGEN LIMITED<BR>
TEL (02)&nbsp;9878 0088</B><BR>
<U><B>http://www.novogen.com</B></U><BR><BR>
<B>PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE<BR>
COMMUNICATIONS, MARSHALL EDWARDS, INC.<BR>
TEL &#043;1 858-792-3729</B><BR>
<U><B>http://www.marshalledwardsinc.com</B></U><BR><BR>
<B>WESTBROOK COMMUNICATIONS<BR>
IAN WESTBROOK TEL (02)&nbsp;9231 0922</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>w82755w8275500.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w82755w8275500.gif
M1TE&.#EAS0!'`/<``!5<73%D97)V>+$F)K(H*+,I*K$Q,K&'B,R?G]:SL][#
MPN+2T.;<VNSMZ_W\_/___Y#I()$#*)#?&I&`A?___Y%?K)?O!!+A;)?NR!+9
M=!+98```&````!+9.```0````````!+9=!+98````````4``X!H`1"0PJ"4>
MG!+;_!F_$`)P```#K``#J````````#X`/!+9<$````$``SH`0U<`7$X`24\`
M1%,`5W,`7',`>64`=#,`;5P`,G,`36T`:68`=&0`+FP`;```````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````!+;>!C)0)-TNA+;7!F_$````!4``)0`&@`*`MT`
M&0`*`0```````1FZ:````!C2:!+</)$`70`!-0```!F_$`!&MA+;@)#I(!+<
M#)#I()$M@/___Y$M>)%I#@```0@9@I%HU@```````!F_$!8`/)?NR```````
M``@``)?LP)?NR!+A;!+A;`@9@A+<`!+A9AF_$``````!-1+<-)#V7)#V80`!
M-0```!F_$!+<$)%FN!+<>)#I(``!-0``?A+<1("4,!+A+!+A,````!+<>)#V
M7)#V80```!+A,!+A+!+<5!F_$!+@_)#I(```````?A+<B("4,```?A+A,!+A
M#(#G<H#FRP!`!5Z"2````"'Y!```````+`````#-`$<`AQ5<73%D97)V>+$F
M)K(H*+,I*K$Q,K&'B,R?G]:SL][#PN+2T.;<VNSMZ_W\_/___Y#I()$#*)#?
M&I&`A?___Y%?K)?O!!+A;)?NR!+9=!+98```&````!+9.```0````````!+9
M=!+98````````4``X!H`1"0PJ"4>G!+;_!F_$`)P```#K``#J````````#X`
M/!+9<$````$``SH`0U<`7$X`24\`1%,`5W,`7',`>64`=#,`;5P`,G,`36T`
M:68`=&0`+FP`;```````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````!+;>!C)0)-T
MNA+;7!F_$````!4``)0`&@`*`MT`&0`*`0```````1FZ:````!C2:!+</)$`
M70`!-0```!F_$`!&MA+;@)#I(!+<#)#I()$M@/___Y$M>)%I#@```0@9@I%H
MU@```````!F_$!8`/)?NR`````````@``)?LP)?NR!+A;!+A;`@9@A+<`!+A
M9AF_$``````!-1+<-)#V7)#V80`!-0```!F_$!+<$)%FN!+<>)#I(``!-0``
M?A+<1("4,!+A+!+A,````!+<>)#V7)#V80```!+A,!+A+!+<5!F_$!+@_)#I
M(```````?A+<B("4,```?A+A,!+A#(#G<H#FRP!`!5Z"2`````C^`!T('$BP
MH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQHT>$#3Z*'$FRI,F!#$ZJ7,FR
M9<*0+F/*G-DQ)<V;.',V5`!3I\^?.)\I`$JT:,MG_(PJ72I2`0"F4*->7`#`
MIM2K6!=2#9"UJU>"#`!4_4H6:UBQ9=-";2`6`"JU<(VV!?`LKEV?<\?>W3LS
M+X">?`.K#.!7L.&3_/P^/<SXXS/%BQM+SNA4,=?)F"U"!B`@LV>)F^E^'MV0
M\.8%I%,C1!4ZLNK##18L`&R0:NC+'&7/WLA@-FVR!PP(1]`0@?`$#1L$'\"<
M.0$#Q`^V!C"487`#R`\N"$Z@^0`"![+^2TQP@$!WY\_#*Q3.OKW[Z`2O0V]X
M7;Q#`]^[6TUX@#E\_N@U9UYW!/PGD&FA-73>?@(U@%]^`IZ''43&Y3>@A<Q-
M>!!ZYW5XW@$&X6?>`+^%Z%]$!IB'GP'6G9@0`R)^>,!R$+)(T&.M):60`M_9
M2%`"`8(WXX,C@LB0@Q#V>)V``_A84)+>16DD02F.Z"1"*0Y@($,I5CF`?0?U
MIV5""]0(I@,(J-@D06Q-MY"8!B)08W4#*5?C0@T0V"0"OVUG0"NH;6B>1%V.
M>&9!66ZY4)55$O"FBP;E6>1+*ZXYT'0`Z(C0=R3^"*&B`BW@Y90'C<K0H0+E
M1ZB*`R[:':C^"6690):D&@0GEIS66FJN`^'86D)`6CH0A*C622RNW17KD*HH
M=J<`K>N]VJR6/'87:)B0>MK=E0E=V!.F&"`DIGW]X0<K066J>!"0W>DJ$;,0
M9:E`M0-<&Z*T\4HK(K<#W7KOH`[1.R5KK>%6T(ALYL<O0G+B=R:C&<'[D*P.
M[!LKOA-+VP"GH/J++J\9`^Q`F[\:%"RI<CH+D<(%L3L`G19)?%^R(W.,)<8S
MCXDFI^)F*U!_W94(+*?B"3"=I@/)2Z6Z$`'=:;\]:B1S0Q3OW-W-.F><-;2V
M^EPQTQ"-^-]T!H_<*D&30I3NEVCC'+/(6HO'-:)N<XDQO3#_[+7^V*L^1U!B
M)0]T\L?XY4TUQAO3'#'<.8N'][U9Y_P?T-QZW"#1$E%>T'0P9VFORQ/-3:_0
M[YHWX^FG:P@YN5'3'?GAKX,,]>L,8!Y1RE>2#)FFB5\)^JH#3/G[XN=%R9R[
M7[-MK-N)3ALGIX!9[D#MBE/8^HVW#23GZ\/G&[S@T$L]X/@7(E^U]N$G7;>K
MKW_M]^P&)JY\T]<39/1FZ@_`8/=:3UDF?O92B')FM"GS-."`"$P@UAX&MN2=
MJU1U6YMXI.<`ODT+>0CR2TIZ5QO;>0\^\E,66%HAK"<Q#G9GDF#^'@@Y16E.
M;^V#F/,2<IJ=M:^"ZU.("M4''H=0;V'^4[/;_.)SO>9]$"%IHZ#32+<N#TI'
M,77)4HED^)`E$O%J#?EA`1TU+52!S(A:`Q6[6I$2"JZ-A4O#HD(4TQD2+BQE
M+UM9`QUPQBS6CR!!9!^J7)82,$KN8GZCH/L(P$2""*PA?@G`]HK%,H<T;(@"
M\5(AIW?'89U0B,6"F!]A!ROJ?4F0+EN80;SE$+]422'ENJ%!J/>^EC52(5H4
M%!>]5RP)ED>5%\.E`RAW2U")Z'N+DMV1\M*NA1QK(1="52I%*9!8&B2/T8)D
M07B9PUP^D'RJE%0Q05(I9AZD,F)1F4(2T`H+:J=\ZVF2>8K%05D"3X2-JB;6
M'LBNY^`R7=OI.E.:K#01@@'@.\6I40#MQ,]@6NE0[`*B`;NXD'J::X8&E><"
M"$2@U%&TA!%I"S!/%2`#I"Y`R#/1A=(S)(HJE'PH;67^1%BQ'NER5R^MF3D!
M!*61HC$AE='?0Y!44PFQ]$<Q&NF%,#HLXQF56P]B:>+D&:;@_-1I:%3.@P0T
M'XR(90`2\5.4P//3=='(.\(Y0`#C@[JREM56P3'<0>!XTXJ$9)(%B4T"$K`;
MC2A``&KUH0+F.E:*,&"O=&703=[ZFL(:]K"(3:QB%\O8QCKVL9"-K&0G2]G*
36O:RF,VL9C?+V<YZ]K,Q"0@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
